| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
75,463,000 as of 6/30 |
| Market
Cap: |
308.64(M) |
| Last
Volume: |
691,399 |
Avg
Vol: |
384,432 |
| 52
Week Range: |
$2.24 - $4.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
Company Profile Immunomedics is a biopharmaceutical company focused on the development of monoclonal antibody-based products for the treatment of cancer, autoimmune and other diseases. Co.'s product candidates include: epratuzumab, a humanized antibody which targets CD22, an antigen found on the surface of B-lymphocytes, a type of white blood cells; and Yttrium-90-labeled clivatuzumab tetraxetan, its therapeutic product candidate for patients with pancreatic cancer. Co. is developing a DOCK-AND-LOCK method with its subsidiary, IBC Pharmaceuticals, Inc., for making fusion proteins and multifunctional antibodies, as well as a method of delivering imaging and therapeutic agents selectively to disease.
|
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2013-03-17 |
2012-12-14 |
2012-06-15 |
2011-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
Stark Don C |
Director |
|
2012-12-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
22,000 |
|
- |
|
Coleman Morton |
Director |
|
2012-12-10 |
4 |
D |
$3.00 |
$15,150 |
I/I |
(5,050) |
0 |
|
- |
|
Coleman Morton |
Director |
|
2012-12-07 |
4 |
D |
$3.03 |
$606 |
I/I |
(200) |
5,050 |
|
- |
|
Coleman Morton |
Director |
|
2012-12-06 |
4 |
D |
$3.00 |
$15,000 |
I/I |
(5,000) |
5,250 |
|
- |
|
Coleman Morton |
Director |
|
2012-12-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
25,000 |
|
- |
|
Stark Don C |
Director |
|
2012-12-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
25,000 |
|
- |
|
Paetzold Mary E |
Director |
|
2012-12-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
28,300 |
|
- |
|
Markison Brian A |
Director |
|
2012-12-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
25,000 |
|
- |
|
Coleman Morton |
Director |
|
2012-12-04 |
4 |
D |
$3.07 |
$15,411 |
I/I |
(5,000) |
10,250 |
|
- |
|
Coleman Morton |
Director |
|
2012-11-30 |
4 |
D |
$3.13 |
$15,671 |
I/I |
(5,000) |
15,250 |
|
- |
|
Coleman Morton |
Director |
|
2012-11-29 |
4 |
D |
$3.14 |
$15,762 |
I/I |
(5,000) |
20,250 |
|
- |
|
Coleman Morton |
Director |
|
2012-11-28 |
4 |
D |
$3.05 |
$15,250 |
I/I |
(5,000) |
25,250 |
|
- |
|
Coleman Morton |
Director |
|
2012-11-27 |
4 |
D |
$3.04 |
$15,242 |
I/I |
(5,000) |
30,250 |
|
- |
|
Coleman Morton |
Director |
|
2012-11-26 |
4 |
D |
$3.00 |
$47,574 |
I/I |
(15,847) |
35,250 |
|
- |
|
Coleman Morton |
Director |
|
2012-11-23 |
4 |
D |
$3.00 |
$4,959 |
I/I |
(1,653) |
51,097 |
|
- |
|
Coleman Morton |
Director |
|
2012-11-21 |
4 |
D |
$2.96 |
$14,806 |
I/I |
(5,000) |
52,750 |
|
- |
|
Coleman Morton |
Director |
|
2012-11-19 |
4 |
D |
$3.04 |
$7,611 |
I/I |
(2,500) |
57,750 |
|
- |
|
Gorman Gerard G |
SVP, Fin. , and CFO |
|
2012-08-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
115,671 |
|
- |
|
Goldenberg Cynthia L |
President and CEO |
|
2012-08-27 |
4 |
A |
$0.00 |
$0 |
I/I |
85,700 |
2,891,486 |
|
- |
|
Goldenberg David M |
See Remarks |
|
2012-08-27 |
4 |
A |
$0.00 |
$0 |
D/D |
85,700 |
2,891,486 |
|
- |
|
Goldenberg David M |
See Remarks |
|
2012-08-27 |
4 |
A |
$0.00 |
$0 |
I/I |
100,000 |
579,905 |
|
- |
|
Goldenberg Cynthia L |
President and CEO |
|
2012-08-27 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
579,905 |
|
- |
|
Goldenberg David M |
See Remarks |
|
2012-04-19 |
5 |
GD |
$0.00 |
$0 |
I/I |
181,729 |
3,189,815 |
|
- |
|
Goldenberg Cynthia L |
President and CEO |
|
2012-04-19 |
5 |
GD |
$0.00 |
$0 |
D/D |
181,729 |
3,008,086 |
|
- |
|
Goldenberg Cynthia L |
President and CEO |
|
2012-04-16 |
5 |
GA |
$0.00 |
$0 |
D/D |
181,729 |
3,189,815 |
|
- |
|
89 Records found
|
|
Page 1 of 4 |
|
|